期刊文献+

爱普列特在治疗良性前列腺增生中的应用 被引量:4

原文传递
导出
摘要 作为一个新上市的5α-2还原酶抑制剂,相应的临床研究还很不完善,有许多问题诸如服用爱普列特与PSA水平下降的量化关系、服用爱普列特的长期疗效和安全性以及毒副作用等都需要进一步研究。总体来讲,依据目前所能获得的研究资料,我们认为爱普列特可以显著地缩小前列腺体积,改善BPH患者症状,在这些方面与非那雄胺所取得的临床效果有良好的可比性,是一种较理想的治疗BPH的药物。
出处 《国际泌尿系统杂志》 2009年第4期492-495,共4页 International Journal of Urology and Nephrology
关键词 前列腺增生
  • 相关文献

参考文献16

  • 1Hudson PB,Boake R,Trachtenberg J,et al.Efficacy of finas2 teride is maintained in patients with benign prostatic hyperplasia treated for 5 years.The North American F-inastetide Study Group.Urology,1999,53(4):690 -695.
  • 2Audet PR,Baine NH,Benincosa LJ,et al.Epristeride steroid 5a-reductase inh-ibitor treatment for benign prostatic hyperplasia.Zqs Ⅵ,1994,19(7):646 -650.
  • 3Sun ZY,Wu H Y,Wang MY,et al.The mechanism of epris2 teride against benign prostatic hyperplasia.Eur J Pharma col,1999,371 (223):227-233.
  • 4Wu SF,SUn HZ,Qi XD.Effect of epristeride on the ex2 preeaion of IGF21 and TGF-2 beta receptors in androgen2 induced castrated rat prostate.Exp Biol Med (Maywood),2001,226 (10):954-960.
  • 5Robinson EJ,Collins AF.Effects of a new 5 alpha reductase inhibitor (epristeride) On human prostate cell cultures.Prostate,1997,32 (4):259-265.
  • 6Sun ZY,Feng J,Qi XD,et al.Reversible long term toxicity of epristeride in beagle dogs.Toxicol Appl Pharmacol,1999,154 (2):145 -152
  • 7朱刚,王建业,刘俊达,王舒,万奔,邓庶民,朱生才,左韬,刘明,张耀光.雌雄激素对前列腺基质细胞增殖的影响[J].中华泌尿外科杂志,2000,21(6):361-363. 被引量:31
  • 8李家泰,郑直,金杰,李天云,李华,王婉青.爱普列特正常人体耐受性研究[J].中国临床药理学杂志,2000,16(6):419-423. 被引量:6
  • 9李家泰,郑直,金杰,李天云,李华,王婉青.爱普列特正常人体药代动力学研究[J].中国临床药理学杂志,2000,16(6):424-428. 被引量:11
  • 10薛兆英,韩文科,金杰,张元芳,丁强,王晓雄,曹立军.爱普列特治疗良性前列腺增生Ⅱ期临床研究[J].中国临床药理学杂志,2000,16(6):432-435. 被引量:25

二级参考文献16

  • 1[1]Audet. PH., Lamb Y, Jorkasky D, et al. Effect of multiple doses of epristends, a steroid 5a- reductase inhibitor, on serum dihydrotestos- terone in older male subjects. Clin Pharmacol Ther, 1993; 53: 231.
  • 2[2]Johnsonbaugh RE, Cohen BR, McCormack, EM, et al. Effect of fourteen days treatment with epristeride, an uncompetitive 5a- reductase inhibitor. on serum and prostatic testosterone and dihydrotestosterone in men with benign prostatic hyperpiasia. J Urol, 1993; 149: 423a.
  • 3[3]Depre M, Meeter C, Hecken AV, et al. Pharmacodynamics and tolerability of L-654,066, a steroid 5a- reductase inhibitor, in men. Clin Pharmacol Ther, 1992; 52: 409~412.
  • 4[4]Boppana VB, et al. Normal - phase high performance liquid chromto- graphic determination of epristeride, a prestatic steroid 5a- reductase enzyme inhibitor, inhuman plasma. J Chromatogr, 1993; 631: 251~254.
  • 5[5]P.R. Audet. Epristeride, Drugs Future, 1994; 19: 646~650.
  • 6Levine A C,Endocrinology,1992年,130期,2413页
  • 7Audet PN H,Lamb Y,Jorkasky D,et al.Effect of multiple doses ofepristends, a steroid 5a-reductase inhibitor, on serum dihydrotestosterone.in older male subjects[].Clinical Pharmacology and Therapeutics.1993
  • 8Johnsonbaugh RE,Cohen BR,McCormack,EM,et al.Effect of fourteendays treatment with epristeride, an uncompetitive 5a- reductase inhibitoron serum and prostatic testosterone and dihydrotestosterone in men withbenign prostatic hyperpiasia[].Journal d Urologie.1993
  • 9Depre M,Meeter C,Hecken AV,et al.Pharmacodynamics and tolerability of L-654,066, a steroid 5a - reductase inhibitor, in men[].Clinical Pharmacology and Therapeutics.1992
  • 10Audet PR,Epristeride. Drugs of the Future . 1994

共引文献86

同被引文献63

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部